Latest news from Ketchum PR, NYC on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/pfizer-consumer-healthcare-responds-to-phs-ii-findings-with-statement-and-centrum-silver-multivitamin-b-roll-and-photo-assets/?sc=rsin /articles/pfizer-consumer-healthcare-responds-to-phs-ii-findings-with-statement-and-centrum-silver-multivitamin-b-roll-and-photo-assets/?sc=rsin Wed, 17 Oct 2012 10:30:00 EST Pfizer Consumer Healthcare is very pleased that study investigators at Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, chose Centrum(r) Silver(r) for the Physicians' Health Study II. The Centrum(r) multivitamins' quality, among other factors, led investigators to choose Centrum(r) Silver(r) for inclusion in the study. Centrum(r) Silver(r) multivitamins currently available in stores have since been updated and improved to reflect advances in nutritional science. Ketchum PR, NYC /articles/arthritis-advisory-committee-recommends-fda-approval-of-febuxostat-for-the-treatment-of-hyperuricemia-in-patients-with-gout/?sc=rsin /articles/arthritis-advisory-committee-recommends-fda-approval-of-febuxostat-for-the-treatment-of-hyperuricemia-in-patients-with-gout/?sc=rsin Tue, 25 Nov 2008 09:00:00 EST Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in favor of approval, with one panel member abstaining. The vote followed presentations by Takeda Global Research & Development Center, Inc., the FDA, and invited guest speakers. If approved in the United States by the FDA, febuxostat will be the first new treatment for the management of hyperuricemia associated with gout in more than 40 years. Ketchum PR, NYC /articles/amitiza-r-lubiprostone-8-mcg-now-available-to-treat-irritable-bowel-syndrome-with-constipation-in-adult-women/?sc=rsin /articles/amitiza-r-lubiprostone-8-mcg-now-available-to-treat-irritable-bowel-syndrome-with-constipation-in-adult-women/?sc=rsin Tue, 27 May 2008 12:30:00 EST Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. today announced that AMITIZA (R) (lubiprostone) 8 mcg capsules are now available by prescription in pharmacies across the U.S. for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years and older. AMITIZA 24 mcg capsules have been available by prescription to treat Chronic Idiopathic Constipation in adults since 2006. Ketchum PR, NYC /articles/new-amitiza-8-mcg-phase-iii-studies-demonstrated-overall-symptom-improvement-in-adult-women-with-irritable-bowel-syndrome-with-constipation-ibs-c/?sc=rsin /articles/new-amitiza-8-mcg-phase-iii-studies-demonstrated-overall-symptom-improvement-in-adult-women-with-irritable-bowel-syndrome-with-constipation-ibs-c/?sc=rsin Mon, 19 May 2008 08:45:00 EST New study results indicated that treatment with AMITIZA (lubiprostone) 8 mcg lead to significant relief of overall symptoms of Irritable Bowel Syndrome with Constipation (IBS-C). These results were presented at Digestive Disease Week (DDW) 2008, the largest annual international meeting of digestive disease specialists. Ketchum PR, NYC /articles/actos-pioglitazone-hcl-prevented-progression-of-atherosclerotic-plaque-volume-in-patients-with-type-2-diabetes/?sc=rsin /articles/actos-pioglitazone-hcl-prevented-progression-of-atherosclerotic-plaque-volume-in-patients-with-type-2-diabetes/?sc=rsin Mon, 31 Mar 2008 11:30:00 EST New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS (pioglitazone HCl) reduced the atherosclerotic burden in the coronary arteries compared to glimepiride, and prevented progression compared to baseline. These data stem from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial. Ketchum PR, NYC /articles/ramelteon-did-not-exacerbate-respiratory-depressant-effects-in-patients-with-moderate-to-severe-copd/?sc=rsin /articles/ramelteon-did-not-exacerbate-respiratory-depressant-effects-in-patients-with-moderate-to-severe-copd/?sc=rsin Tue, 04 Dec 2007 08:50:00 EST A new study presented today showed that ramelteon did not exacerbate respiratory depressant effects in patients (40 years and older) with moderate to severe chronic obstructive pulmonary disease (COPD), as measured by oxygenation or abnormal breathing events relative to placebo. Results of this double-blind, placebo-controlled trial were presented at the 53rd International Respiratory Congress of the American Association for Respiratory Care. Ketchum PR, NYC /articles/takeda-statement-on-actos-pioglitazone-hcl-meta-analysis-published-in-jama/?sc=rsin /articles/takeda-statement-on-actos-pioglitazone-hcl-meta-analysis-published-in-jama/?sc=rsin Tue, 11 Sep 2007 16:55:00 EST Takeda Pharmaceuticals North America, Inc. is aware of the review of ACTOS (pioglitazone HCl) data conducted by A. Michael Lincoff, M.D., and colleagues at the Cleveland Clinic, published in the Journal of the American Medical Association which concluded that ACTOS is associated with a significantly lower risk of heart attack, stroke, or death among a diverse population of 16,390 patients with diabetes versus control therapy. Ketchum PR, NYC /articles/worldsleep-2007-ramelteon-demonstrates-sustained-efficacy-over-six-months-in-adults-with-chronic-insomnia/?sc=rsin /articles/worldsleep-2007-ramelteon-demonstrates-sustained-efficacy-over-six-months-in-adults-with-chronic-insomnia/?sc=rsin Fri, 31 Aug 2007 13:00:00 EST Data from a six-month study of ramelteon will be presented in poster format at worldsleep07: The 5th World Congress of the World Federation of Sleep Research and Sleep Medicine Societies to be held in Cairns, Australia September 2-6, 2007. This large clinical study demonstrated that ramelteon was effective in reducing time to fall asleep for up to six months versus placebo in adult patients with chronic insomnia. Ketchum PR, NYC /articles/new-drug-application-for-lubiprostone-to-treat-irritable-bowel-syndrome-with-constipation/?sc=rsin /articles/new-drug-application-for-lubiprostone-to-treat-irritable-bowel-syndrome-with-constipation/?sc=rsin Thu, 12 Jul 2007 12:00:00 EST Sucampo Pharmaceuticals, Inc., (Sucampo Pharmaceuticals) today announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C). Ketchum PR, NYC /articles/subsets-of-landmark-diabetes-trials-investigating-macrovascular-outcomes-presented/?sc=rsin /articles/subsets-of-landmark-diabetes-trials-investigating-macrovascular-outcomes-presented/?sc=rsin Mon, 25 Jun 2007 09:00:00 EST Multiple Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions regarding ACTOS, Takeda's treatment for Type 2 diabetes Ketchum PR, NYC /articles/investigational-dpp-4-inhibitor-demonstrated-efficacy-in-reducing-glucose-levels/?sc=rsin /articles/investigational-dpp-4-inhibitor-demonstrated-efficacy-in-reducing-glucose-levels/?sc=rsin Mon, 25 Jun 2007 09:00:00 EST The first ever human data for Alogliptin, Takeda's investigational compound for Type 2 diabetes, being presented at the ADA annual meeting going on in Chicago, IL. Alogliptin, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes, demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study. Ketchum PR, NYC /articles/no-significant-impairment-in-middle-of-the-night-balance-mobility-or-memory-in-older-adults-using-ramelteon/?sc=rsin /articles/no-significant-impairment-in-middle-of-the-night-balance-mobility-or-memory-in-older-adults-using-ramelteon/?sc=rsin Tue, 22 May 2007 18:00:00 EST A new study presented today showed that ramelteon did not impair middle-of-the-night balance, mobility or memory performance in older adults with insomnia, relative to placebo. This study also demonstrated, as in previous studies, that patients treated with zolpidem did have impaired performances on these measures, as compared to placebo. Ketchum PR, NYC /articles/lubiprostone-may-improve-symptom-relief-rates-in-adults-with-irritable-bowel-syndrome-with-constipation/?sc=rsin /articles/lubiprostone-may-improve-symptom-relief-rates-in-adults-with-irritable-bowel-syndrome-with-constipation/?sc=rsin Mon, 21 May 2007 08:45:00 EST A new study demonstrated that the active ingredient in AMITIZAA(r) (lubiprostone), given 8 mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C). Ketchum PR, NYC /articles/dr-judith-reichman-addresses-millions-of-american-women/?sc=rsin /articles/dr-judith-reichman-addresses-millions-of-american-women/?sc=rsin Mon, 12 Mar 2007 09:50:00 EST Dr. Judith Reichman, a well-known women's health specialist, is giving women food for thought with "Straight Talk on Women's GI Health" (www.GIStraightTalk.com), a new campaign about digestive health. Ketchum PR, NYC /articles/new-data-show-actos-pioglitazone-hcl-halted-progression/?sc=rsin /articles/new-data-show-actos-pioglitazone-hcl-halted-progression/?sc=rsin Mon, 13 Nov 2006 12:05:00 EST Results demonstrated significant improvements on cardiovascular markers beyond glycemic control. Ketchum PR, NYC /articles/actos-pioglitazone-hcl-demonstrates-significant-improvements-in-cardiovascular-outcomes/?sc=rsin /articles/actos-pioglitazone-hcl-demonstrates-significant-improvements-in-cardiovascular-outcomes/?sc=rsin Thu, 14 Sep 2006 17:00:00 EST Several abstracts presented today at the 42nd Annual Meeting of the European Association for the Study of Diabetes (EASD) indicated that ACTOSA(r) (pioglitazone HCl), an oral antidiabetic medication, demonstrated significant cardiovascular benefits such as reducing the risk of heart attack and/or stroke and acute coronary syndrome in patients with type 2 diabetes. Ketchum PR, NYC /articles/actos-shows-reduced-risk-of-secondary-stroke-by-almost-50-percent/?sc=rsin /articles/actos-shows-reduced-risk-of-secondary-stroke-by-almost-50-percent/?sc=rsin Tue, 05 Sep 2006 10:25:00 EST Results of new analyses found that ACTOSA(r) (pioglitazone HCl), an oral antidiabetic medication, significantly reduced the risk of recurrent stroke in high-risk patients with type 2 diabetes. The findings were presented today in a late-breaker session at the World Congress of Cardiology in Barcelona. Ketchum PR, NYC /articles/rozerem-ramelteon-shown-to-be-effective-in-a-first-night-effect-model/?sc=rsin /articles/rozerem-ramelteon-shown-to-be-effective-in-a-first-night-effect-model/?sc=rsin Mon, 19 Jun 2006 10:00:00 EST Data presented at the SLEEP 2006 20th Anniversary Meeting of the Associated Professional Sleep Societies have shown that ROZEREMTM (ramelteon) reduced time to fall asleep with no evidence of next-day residual effects, including psychomotor and memory effects, in a first-night-effect model of transient insomnia. The results of this double-blind, randomized study were presented as a poster presentation. Ketchum PR, NYC /articles/amitiza-lubiprostone-may-help-improve-symptoms-of-irritable-bowel-syndrome-with-constipation/?sc=rsin /articles/amitiza-lubiprostone-may-help-improve-symptoms-of-irritable-bowel-syndrome-with-constipation/?sc=rsin Mon, 22 May 2006 10:20:00 EST A new study found that AMITIZAa" cents (lubiprostone) may help relieve the symptoms associated with constipation-predominant irritable bowel syndrome (IBS-C). IBS is a condition that affects nearly 30 million people in North America and accounts for 25-50 percent of referrals to gastroenterologists. The study was presented today at Digestive Disease Week, the largest annual meeting of digestive disease specialists. Ketchum PR, NYC /articles/amitiza-effective-well-tolerated-in-people-older-than-age-65/?sc=rsin /articles/amitiza-effective-well-tolerated-in-people-older-than-age-65/?sc=rsin Mon, 22 May 2006 10:20:00 EST AMITIZAa" cents (lubiprostone), the first selective chloride channel activator for the treatment of chronic idiopathic constipation, was effective and well-tolerated in treating the symptoms of chronic idiopathic constipation in the elderly adult population according to findings presented during a poster session today at Digestive Disease Week 2006. Ketchum PR, NYC